LIBTAYO 350 mg concentrate for solution for infusion. clinical trials
4 indexed studies · 1 currently recruiting
- RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
This study is testing a new medicine, cemiplimab (also known as Libtayo), for a type of skin cancer called cutaneous squamous cell carcinoma. Doctors want to see if giving this medicine before surgery can completely clear the cancer cells at the original site.
For: Stage II to IV cutaneous squamous cell carcinomaGermany - AuthorisedTherapeutic exploratory (Phase II)
RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer
This study is looking at a treatment for people with early-stage (Stage I) non-small cell lung cancer who cannot have surgery. Researchers want to see if three doses of an immunotherapy drug called cemiplimab can safely keep the cancer under control without needing major operations or intensive radiotherapy.
For: Stage I non-small cell lung cancerNetherlands - AuthorisedTherapeutic exploratory (Phase II)
A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT
This study tests whether an immunotherapy medicine called Libtayo can shrink a type of skin cancer called cutaneous squamous cell carcinoma. Researchers want to see if using this drug first can help patients safely avoid having surgery, protecting healthy skin and sensitive areas like the face.
For: cutaneous squamous cell carcinomaItaly - AuthorisedTherapeutic exploratory (Phase II)
Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.
This study is looking at how a medicine called cemiplimab (Libtayo) works in people with advanced skin cancer (cutaneous squamous cell carcinoma). Researchers want to understand why some people respond well and others don't, by studying blood and tumour samples.
For: Cutaneous squamous cell carcinoma (ccSCC)Spain